- call +1-201-465-4211
- email sales@mrinsights.biz
Chemotherapy is widely used as to target the neoplastic cells. However, this therapy is effective against most of the cancer, but the cells of the hematopoietic system that produces billions of blood cells needed daily are highly sensitive to this therapy and result in loss of blood cell population. This condition is known as the chemotherapy-induced neutropenia. In chemotherapy-induced neutropenia, the body has a low level of neutrophils which are types of white blood cells. Neutrophils are body’s defense system against infections. Neutrophils fight against infection by destroying fungi, bacteria or yeast. Neutropenia occurs in about half of the people receiving chemotherapy. People with chemotherapy-induced neutropenia are most likely to develop infection and fever. It can also lead to delay in treatment and reduction in chemotherapy dose intensity. Chemotherapy-induced neutropenia is most likely to occur in cancer that directly affects the bone marrow such as leukemia. Chemotherapy-induced neutropenia patients mostly require hospitalization and cost of the treatment also increase with the anti-infective treatment.
Scope of the Report:
This report studies the Chemotherapy-Induced Neutropenia Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Chemotherapy-Induced Neutropenia Treatment market by product type and applications/end industries.
Chemotherapy is the most preferred choice of treatment for cancer. Increasing use of chemotherapy will drive the growth of chemotherapy-induced neutropenia treatment market.
The global Chemotherapy-Induced Neutropenia Treatment market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Chemotherapy-Induced Neutropenia Treatment.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Amgen
Sanofi
Novartis
Baxter International
Teva Pharmaceuticals Industries
Apotex
Dr.Reddy’S Laboratory
Biogenomics
Ligand Pharmaceuticals
NAL Pharmaceuticals
Coherus BioSciences
Intas Pharmaceuticals
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Antibiotic Therapy
Colony-Stimulating Factor Therapy
Granulocyte Transfusion
Splenectomy Procedure
Others
Market Segment by Applications, can be divided into
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Chemotherapy-Induced Neutropenia Treatment Market Overview
1.1 Product Overview and Scope of Chemotherapy-Induced Neutropenia Treatment
1.2 Classification of Chemotherapy-Induced Neutropenia Treatment by Types
1.2.1 Global Chemotherapy-Induced Neutropenia Treatment Revenue Comparison by Types (2017-2023)
1.2.2 Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Types in 2017
1.2.3 Antibiotic Therapy
1.2.4 Colony-Stimulating Factor Therapy
1.2.5 Granulocyte Transfusion
1.2.6 Splenectomy Procedure
1.2.7 Others
1.3 Global Chemotherapy-Induced Neutropenia Treatment Market by Application
1.3.1 Global Chemotherapy-Induced Neutropenia Treatment Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Global Chemotherapy-Induced Neutropenia Treatment Market by Regions
1.4.1 Global Chemotherapy-Induced Neutropenia Treatment Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Chemotherapy-Induced Neutropenia Treatment Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Chemotherapy-Induced Neutropenia Treatment Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Chemotherapy-Induced Neutropenia Treatment Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Chemotherapy-Induced Neutropenia Treatment Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Chemotherapy-Induced Neutropenia Treatment Status and Prospect (2013-2023)
1.5 Global Market Size of Chemotherapy-Induced Neutropenia Treatment (2013-2023)
2 Manufacturers Profiles
2.1 Amgen
2.1.1 Business Overview
2.1.2 Chemotherapy-Induced Neutropenia Treatment Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Amgen Chemotherapy-Induced Neutropenia Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.2 Sanofi
2.2.1 Business Overview
2.2.2 Chemotherapy-Induced Neutropenia Treatment Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Sanofi Chemotherapy-Induced Neutropenia Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.3 Novartis
2.3.1 Business Overview
2.3.2 Chemotherapy-Induced Neutropenia Treatment Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Novartis Chemotherapy-Induced Neutropenia Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.4 Baxter International
2.4.1 Business Overview
2.4.2 Chemotherapy-Induced Neutropenia Treatment Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Baxter International Chemotherapy-Induced Neutropenia Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.5 Teva Pharmaceuticals Industries
2.5.1 Business Overview
2.5.2 Chemotherapy-Induced Neutropenia Treatment Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Teva Pharmaceuticals Industries Chemotherapy-Induced Neutropenia Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.6 Apotex
2.6.1 Business Overview
2.6.2 Chemotherapy-Induced Neutropenia Treatment Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Apotex Chemotherapy-Induced Neutropenia Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.7 Dr.Reddy’S Laboratory
2.7.1 Business Overview
2.7.2 Chemotherapy-Induced Neutropenia Treatment Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Dr.Reddy’S Laboratory Chemotherapy-Induced Neutropenia Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.8 Biogenomics
2.8.1 Business Overview
2.8.2 Chemotherapy-Induced Neutropenia Treatment Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Biogenomics Chemotherapy-Induced Neutropenia Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.9 Ligand Pharmaceuticals
2.9.1 Business Overview
2.9.2 Chemotherapy-Induced Neutropenia Treatment Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Ligand Pharmaceuticals Chemotherapy-Induced Neutropenia Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.10 NAL Pharmaceuticals
2.10.1 Business Overview
2.10.2 Chemotherapy-Induced Neutropenia Treatment Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 NAL Pharmaceuticals Chemotherapy-Induced Neutropenia Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.11 Coherus BioSciences
2.11.1 Business Overview
2.11.2 Chemotherapy-Induced Neutropenia Treatment Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Coherus BioSciences Chemotherapy-Induced Neutropenia Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.12 Intas Pharmaceuticals
2.12.1 Business Overview
2.12.2 Chemotherapy-Induced Neutropenia Treatment Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Intas Pharmaceuticals Chemotherapy-Induced Neutropenia Treatment Revenue, Gross Margin and Market Share (2016-2017)
3 Global Chemotherapy-Induced Neutropenia Treatment Market Competition, by Players
3.1 Global Chemotherapy-Induced Neutropenia Treatment Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Chemotherapy-Induced Neutropenia Treatment Players Market Share
3.2.2 Top 10 Chemotherapy-Induced Neutropenia Treatment Players Market Share
3.3 Market Competition Trend
4 Global Chemotherapy-Induced Neutropenia Treatment Market Size by Regions
4.1 Global Chemotherapy-Induced Neutropenia Treatment Revenue and Market Share by Regions
4.2 North America Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
4.3 Europe Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
4.5 South America Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
5 North America Chemotherapy-Induced Neutropenia Treatment Revenue by Countries
5.1 North America Chemotherapy-Induced Neutropenia Treatment Revenue by Countries (2013-2018)
5.2 USA Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
5.3 Canada Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
5.4 Mexico Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
6 Europe Chemotherapy-Induced Neutropenia Treatment Revenue by Countries
6.1 Europe Chemotherapy-Induced Neutropenia Treatment Revenue by Countries (2013-2018)
6.2 Germany Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
6.3 UK Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
6.4 France Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
6.5 Russia Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
6.6 Italy Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Chemotherapy-Induced Neutropenia Treatment Revenue by Countries
7.1 Asia-Pacific Chemotherapy-Induced Neutropenia Treatment Revenue by Countries (2013-2018)
7.2 China Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
7.3 Japan Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
7.4 Korea Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
7.5 India Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
8 South America Chemotherapy-Induced Neutropenia Treatment Revenue by Countries
8.1 South America Chemotherapy-Induced Neutropenia Treatment Revenue by Countries (2013-2018)
8.2 Brazil Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
8.3 Argentina Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
8.4 Colombia Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Chemotherapy-Induced Neutropenia Treatment by Countries
9.1 Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Revenue by Countries (2013-2018)
9.2 Saudi Arabia Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
9.3 UAE Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
9.4 Egypt Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
9.5 Nigeria Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
9.6 South Africa Chemotherapy-Induced Neutropenia Treatment Revenue and Growth Rate (2013-2018)
10 Global Chemotherapy-Induced Neutropenia Treatment Market Segment by Type
10.1 Global Chemotherapy-Induced Neutropenia Treatment Revenue and Market Share by Type (2013-2018)
10.2 Global Chemotherapy-Induced Neutropenia Treatment Market Forecast by Type (2018-2023)
10.3 Antibiotic Therapy Revenue Growth Rate (2013-2023)
10.4 Colony-Stimulating Factor Therapy Revenue Growth Rate (2013-2023)
10.5 Granulocyte Transfusion Revenue Growth Rate (2013-2023)
10.6 Splenectomy Procedure Revenue Growth Rate (2013-2023)
10.7 Others Revenue Growth Rate (2013-2023)
11 Global Chemotherapy-Induced Neutropenia Treatment Market Segment by Application
11.1 Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Application (2013-2018)
11.2 Chemotherapy-Induced Neutropenia Treatment Market Forecast by Application (2018-2023)
11.3 Hospital Pharmacy Revenue Growth (2013-2018)
11.4 Retail Pharmacy Revenue Growth (2013-2018)
11.5 Online Pharmacy Revenue Growth (2013-2018)
12 Global Chemotherapy-Induced Neutropenia Treatment Market Size Forecast (2018-2023)
12.1 Global Chemotherapy-Induced Neutropenia Treatment Market Size Forecast (2018-2023)
12.2 Global Chemotherapy-Induced Neutropenia Treatment Market Forecast by Regions (2018-2023)
12.3 North America Chemotherapy-Induced Neutropenia Treatment Revenue Market Forecast (2018-2023)
12.4 Europe Chemotherapy-Induced Neutropenia Treatment Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Chemotherapy-Induced Neutropenia Treatment Revenue Market Forecast (2018-2023)
12.6 South America Chemotherapy-Induced Neutropenia Treatment Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Chemotherapy-Induced Neutropenia Treatment Picture
Table Product Specifications of Chemotherapy-Induced Neutropenia Treatment
Table Global Chemotherapy-Induced Neutr
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
